Citadel Advisors’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $66M | Buy |
1,714,927
+275,933
| +19% | +$10.2M | 0.01% | 1121 |
|
|
2025
Q4 | $51.1M | Sell |
1,438,994
-228,813
| -14% | -$6.43M | 0.01% | 1386 |
|
|
2025
Q3 | $23.9M | Buy |
1,667,807
+1,046,572
| +168% | +$12.4M | ﹤0.01% | 2106 |
|
|
2025
Q2 | $4.46M | Buy |
621,235
+131,547
| +27% | +$729K | ﹤0.01% | 4320 |
|
|
2025
Q1 | $2.93M | Buy |
489,688
+392,025
| +401% | +$3.07M | ﹤0.01% | 4804 |
|
|
2024
Q4 | $762K | Buy |
97,663
+88,016
| +912% | +$877K | ﹤0.01% | 7607 |
|
|
2024
Q3 | $104K | Buy |
9,647
+603
| +7% | +$5.87K | ﹤0.01% | 11062 |
|
|
2024
Q2 | $76.2K | Sell |
9,044
-122,847
| -93% | -$932K | ﹤0.01% | 11266 |
|
|
2024
Q1 | $886K | Sell |
131,891
-508,880
| -79% | -$3.15M | ﹤0.01% | 7163 |
|
|
2023
Q4 | $3.77M | Buy |
640,771
+580,166
| +957% | +$4.45M | ﹤0.01% | 4243 |
|
|
2023
Q3 | $591K | Sell |
60,605
-74,162
| -55% | -$880K | ﹤0.01% | 7697 |
|
|
2023
Q2 | $1.6M | Sell |
134,767
-1,161,005
| -90% | -$13.3M | ﹤0.01% | 5572 |
|
|
2023
Q1 | $14M | Sell |
1,295,772
-558,548
| -30% | -$7.14M | ﹤0.01% | 2366 |
|
|
2022
Q4 | $21.4M | Buy |
1,854,320
+522,040
| +39% | +$6.47M | 0.01% | 1896 |
|
|
2022
Q3 | $19.9M | Buy |
1,332,280
+260,766
| +24% | +$3.57M | ﹤0.01% | 1883 |
|
|
2022
Q2 | $9.66M | Buy |
1,071,514
+1,006,013
| +1,536% | +$6.87M | ﹤0.01% | 2734 |
|
|
2022
Q1 | $491K | Buy |
+65,501
| New | +$456K | ﹤0.01% | 9442 |
|
|
2021
Q4 | – | Sell |
-14,340
| Closed | -$121K | – | 13880 |
|
|
2021
Q3 | $121K | Buy |
+14,340
| New | +$110K | ﹤0.01% | 12633 |
|
|
2021
Q2 | – | Sell |
-1,303,659
| Closed | -$11.1M | – | 13733 |
|
|
2021
Q1 | $11.1M | Buy |
1,303,659
+446,717
| +52% | +$4.3M | ﹤0.01% | 2819 |
|
|
2020
Q4 | $9.62M | Buy |
856,942
+850,691
| +13,609% | +$9.35M | ﹤0.01% | 2686 |
|
|
2020
Q3 | $59K | Buy |
6,251
+2,250
| +56% | +$23.5K | ﹤0.01% | 9537 |
|
|
2020
Q2 | $7K | Sell |
4,001
-827
| -17% | -$1.53K | ﹤0.01% | 9658 |
|
|
2020
Q1 | $8K | Buy |
+4,828
| New | +$13.4K | ﹤0.01% | 9446 |
|
|
2019
Q2 | – | Sell |
-5,182
| Closed | -$91K | – | 9237 |
|
|
2019
Q1 | $91K | Buy |
+5,182
| New | +$88.6K | ﹤0.01% | 8591 |
|
|
2018
Q4 | – | Sell |
-5,699
| Closed | -$235K | – | 9171 |
|
|
2018
Q3 | $235K | Buy |
+5,699
| New | +$321K | ﹤0.01% | 7976 |
|
|
2018
Q2 | – | Sell |
-9,350
| Closed | -$416K | – | 8863 |
|
|
2018
Q1 | $416K | Buy |
+9,350
| New | +$416K | ﹤0.01% | 6217 |
|
Other funds holding COGT
DM
VPM
VCM
FFM
RI
TCM
Citadel Advisors's COGT Position: Q1 2026 in Review
Citadel Advisors increased its Cogent Biosciences (COGT) stake by 19% in Q1 2026, buying an estimated $10.2M and bringing the position to 1,714,927 shares worth $66M. The position accounts for 0.01% of the portfolio, ranked #1121.
Citadel Advisors first reported a position in COGT in Q1 2018 and has held it in 26 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.
- Citadel Advisors held 1,714,927 shares of Cogent Biosciences worth $66M as of Q1 2026.
- Citadel Advisors bought 275,933 Cogent Biosciences shares in Q1 2026, an estimated $10.2M.
- Cogent Biosciences made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1121 holding.
- Citadel Advisors first reported a position in Cogent Biosciences in Q1 2018 and has held it in 26 quarters since.
- 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.